Motley Fool Wealth Management Has Increased By $305,048 Its Genomic Health (GHDX) Position; Contrarius Investment Management LTD Has Lowered Its Boston Beer (SAM) Holding

April 10, 2018 - By Clifton Ray

Genomic Health, Inc. (NASDAQ:GHDX) Logo

Contrarius Investment Management Ltd decreased Boston Beer Inc (SAM) stake by 72.27% reported in 2017Q4 SEC filing. Contrarius Investment Management Ltd sold 22,657 shares as Boston Beer Inc (SAM)’s stock declined 2.25%. The Contrarius Investment Management Ltd holds 8,695 shares with $1.66M value, down from 31,352 last quarter. Boston Beer Inc now has $2.42 billion valuation. The stock increased 3.35% or $6.8 during the last trading session, reaching $210.05. About 61,483 shares traded. The Boston Beer Company, Inc. (NYSE:SAM) has risen 25.34% since April 10, 2017 and is uptrending. It has outperformed by 13.79% the S&P500.

Motley Fool Wealth Management Llc increased Genomic Health Inc (GHDX) stake by 6.06% reported in 2017Q4 SEC filing. Motley Fool Wealth Management Llc acquired 8,972 shares as Genomic Health Inc (GHDX)’s stock declined 13.76%. The Motley Fool Wealth Management Llc holds 156,919 shares with $5.37M value, up from 147,947 last quarter. Genomic Health Inc now has $1.11B valuation. The stock increased 1.29% or $0.4 during the last trading session, reaching $31.33. About 23,825 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has declined 2.07% since April 10, 2017 and is downtrending. It has underperformed by 13.62% the S&P500.

Among 16 analysts covering Boston Beer Co (NYSE:SAM), 1 have Buy rating, 2 Sell and 13 Hold. Therefore 6% are positive. Boston Beer Co had 59 analyst reports since July 28, 2015 according to SRatingsIntel. Berenberg upgraded the shares of SAM in report on Monday, December 18 to “Hold” rating. The company was upgraded on Tuesday, September 26 by Credit Suisse. The stock of The Boston Beer Company, Inc. (NYSE:SAM) earned “Outperform” rating by CLSA on Friday, October 30. The firm has “Sell” rating by Cowen & Co given on Thursday, July 13. Berenberg initiated The Boston Beer Company, Inc. (NYSE:SAM) on Wednesday, January 13 with “Sell” rating. The firm earned “Neutral” rating on Monday, April 25 by Citigroup. The stock of The Boston Beer Company, Inc. (NYSE:SAM) earned “Neutral” rating by Citigroup on Monday, October 30. Credit Suisse maintained The Boston Beer Company, Inc. (NYSE:SAM) rating on Thursday, October 19. Credit Suisse has “Neutral” rating and $151 target. The rating was maintained by Jefferies on Wednesday, April 19 with “Hold”. The firm has “Hold” rating given on Thursday, January 4 by Jefferies.

Contrarius Investment Management Ltd increased Fossil Group Inc (NASDAQ:FOSL) stake by 2.16 million shares to 3.27 million valued at $25.39 million in 2017Q4. It also upped Express Inc (NYSE:EXPR) stake by 2.34 million shares and now owns 3.84M shares. Vale S A (NYSE:VALE) was raised too.

Investors sentiment decreased to 0.87 in Q4 2017. Its down 0.28, from 1.15 in 2017Q3. It worsened, as 25 investors sold SAM shares while 90 reduced holdings. 44 funds opened positions while 56 raised stakes. 8.44 million shares or 3.57% less from 8.75 million shares in 2017Q3 were reported. The North Carolina-based National Bank & Trust Of America De has invested 0% in The Boston Beer Company, Inc. (NYSE:SAM). Tru Com Of Vermont has invested 0.03% in The Boston Beer Company, Inc. (NYSE:SAM). Assetmark owns 4 shares for 0% of their portfolio. Metropolitan Life Com New York invested in 0.01% or 4,888 shares. Us Bank & Trust De owns 578 shares or 0% of their US portfolio. Virtus Advisers reported 2,161 shares stake. Ls Invest Advsr Ltd Liability reported 566 shares. The New York-based Eulav Asset Management has invested 0.09% in The Boston Beer Company, Inc. (NYSE:SAM). California State Teachers Retirement Sys reported 0.01% stake. Alliancebernstein Lp owns 0% invested in The Boston Beer Company, Inc. (NYSE:SAM) for 12,424 shares. Profit Inv Mngmt Lc stated it has 2.15% in The Boston Beer Company, Inc. (NYSE:SAM). Voya Invest Mgmt Ltd Liability Company holds 0% of its portfolio in The Boston Beer Company, Inc. (NYSE:SAM) for 3,778 shares. Wells Fargo Mn reported 0% in The Boston Beer Company, Inc. (NYSE:SAM). Schroder Management Gru invested in 0% or 2,300 shares. Moreover, Legal And General Gru Public Lc has 0% invested in The Boston Beer Company, Inc. (NYSE:SAM) for 7,451 shares.

Since October 31, 2017, it had 0 buys, and 22 selling transactions for $29.70 million activity. Another trade for 773 shares valued at $147,351 was sold by ROPER MARTIN F. $186,750 worth of The Boston Beer Company, Inc. (NYSE:SAM) was sold by Grinnell David L. on Wednesday, December 13. HEATH TARA L. sold $12,090 worth of stock or 64 shares. Geist John C sold $1.53 million worth of stock. Shares for $75,464 were sold by POTTER JONATHAN N.. 5,000 shares were sold by Burwick David A, worth $950,050. Fisher Cheryl sold 93 shares worth $17,569.

Analysts await The Boston Beer Company, Inc. (NYSE:SAM) to report earnings on April, 25. They expect $0.38 earnings per share, down 15.56% or $0.07 from last year’s $0.45 per share. SAM’s profit will be $4.37 million for 138.19 P/E if the $0.38 EPS becomes a reality. After $0.84 actual earnings per share reported by The Boston Beer Company, Inc. for the previous quarter, Wall Street now forecasts -54.76% negative EPS growth.

Among 11 analysts covering Genomic Health (NASDAQ:GHDX), 2 have Buy rating, 3 Sell and 6 Hold. Therefore 18% are positive. Genomic Health had 33 analyst reports since August 5, 2015 according to SRatingsIntel. On Friday, August 28 the stock rating was upgraded by Raymond James to “Market Perform”. As per Wednesday, December 13, the company rating was downgraded by J.P. Morgan. As per Monday, November 23, the company rating was upgraded by UBS. As per Wednesday, December 13, the company rating was downgraded by JP Morgan. On Wednesday, November 4 the stock rating was upgraded by Raymond James to “Outperform”. The firm earned “Buy” rating on Friday, March 9 by Canaccord Genuity. The rating was downgraded by Zacks on Thursday, August 6 to “Hold”. The firm earned “Hold” rating on Friday, October 20 by Jefferies. As per Wednesday, January 6, the company rating was upgraded by Canaccord Genuity. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, November 15.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>